Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379136 | 0.86 | KAT6A (0.52) | ALDH1A1TRPA1MAPK1GSK3BHIF1A | |
| SCHEMBL14023387 | 0.85 | GSK3B (0.48) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL5866992 | 0.83 | MAPT (0.49) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL2377766 | 0.81 | ALDH1A1 (0.51) | MAPTRAB9AEPHX2HTTALDH1A1 | |
| SCHEMBL978712 | 0.81 | AKR1C3 (0.54) | MAPTRAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL1619240 | 0.80 | MAPT (0.52) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL7238448 | 0.79 | MAPT (0.55) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL12719321 | 0.79 | NPC1 (0.49) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL4041375 | 0.78 | MAPT (0.41) | MAPTRAB9ANPC1SMN1; SMN2EPHX2 | |
| SCHEMBL4035515 | 0.78 | MAPT (0.56) | MAPTRAB9ANPC1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012963-B2 | 3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | KUO GEE-HONG | 2010-09-09 | — | — | US | disclosed |
| US-7749995-B2 | 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| WO-2007134149-A2 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227857-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | MAPT 3350/4885RAB9A 4606/4885NPC1 4/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | MAPT 3350/4885RAB9A 4606/4885NPC1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.